Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.

The oncologist - 5 Jan 2024

Rustgi Naryan, Maria Ann, Toumbacaris Nicolas, Zhao HuiYong, Kargus Katherine, Bryant Morgan, Waksmundzki Alexandra, Aricescu Ilinca, Lefkowitz Robert A, Li Bob T, Chou Joanne, Capanu Marinela, de Stanchina Elisa, Misale Sandra, Shia Jinru, Yaeger Rona

Abstract excerpt

BACKGROUND: Cancers with non-V600 BRAF-activating alterations have no matched therapy. Preclinical data suggest that these tumors depend on ERK signaling; however, clinical response to MEK/ERK inhibitors has overall been low. We hypothesized that a narrow therapeutic index, driven by ERK inhibition in healthy (wild-type) tissues, limits the efficacy of these inhibitors. As these mutants signal as activated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to BRAF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 37616543
DOI: 10.1093/oncolo/oyad247
PMCID: PMC10769795

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.PMID 37616543Read ↗

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.Semantic proximity Read ↗

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Semantic proximity Read ↗

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.Semantic proximity Read ↗

The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition.Semantic proximity Read ↗

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.Semantic proximity Read ↗

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.Semantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.Semantic proximity Read ↗

BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.Semantic proximity Read ↗

ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?Semantic proximity Read ↗

Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.Semantic proximity Read ↗

A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.